• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一般人群中重症 COVID-19 的基于人群的风险分层模型的开发与验证

Development and validation of a population-based risk stratification model for severe COVID-19 in the general population.

作者信息

Vela Emili, Carot-Sans Gerard, Clèries Montse, Monterde David, Acebes Xènia, Comella Adrià, García Eroles Luís, Coca Marc, Valero-Bover Damià, Pérez Sust Pol, Piera-Jiménez Jordi

机构信息

Servei Català de la Salut (CatSalut), Barcelona, Spain.

Digitalization for the Sustainability of the Healthcare System (DS3), IDIBELL, Barcelona, Spain.

出版信息

Sci Rep. 2022 Feb 28;12(1):3277. doi: 10.1038/s41598-022-07138-y.

DOI:10.1038/s41598-022-07138-y
PMID:35228558
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8885698/
Abstract

The shortage of recently approved vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has highlighted the need for evidence-based tools to prioritize healthcare resources for people at higher risk of severe coronavirus disease (COVID-19). Although age has been identified as the most important risk factor (particularly for mortality), the contribution of underlying comorbidities is often assessed using a pre-defined list of chronic conditions. Furthermore, the count of individual risk factors has limited applicability to population-based "stratify-and-shield" strategies. We aimed to develop and validate a COVID-19 risk stratification system that allows allocating individuals of the general population into four mutually-exclusive risk categories based on multivariate models for severe COVID-19, a composite of hospital admission, transfer to intensive care unit (ICU), and mortality among the general population. The model was developed using clinical, hospital, and epidemiological data from all individuals among the entire population of Catalonia (North-East Spain; 7.5 million people) who experienced a COVID-19 event (i.e., hospitalization, ICU admission, or death due to COVID-19) between March 1 and September 15, 2020, and validated using an independent dataset of 218,329 individuals with COVID-19 confirmed by reverse transcription-polymerase chain reaction (RT-PCR), who were infected after developing the model. No exclusion criteria were defined. The final model included age, sex, a summary measure of the comorbidity burden, the socioeconomic status, and the presence of specific diagnoses potentially associated with severe COVID-19. The validation showed high discrimination capacity, with an area under the curve of the receiving operating characteristics of 0.85 (95% CI 0.85-0.85) for hospital admissions, 0.86 (0.86-0.97) for ICU transfers, and 0.96 (0.96-0.96) for deaths. Our results provide clinicians and policymakers with an evidence-based tool for prioritizing COVID-19 healthcare resources in other population groups aside from those with higher exposure to SARS-CoV-2 and frontline workers.

摘要

近期获批的针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的疫苗短缺,凸显了基于证据的工具对于为罹患严重冠状病毒病(COVID-19)风险较高人群优先分配医疗资源的必要性。虽然年龄已被确定为最重要的风险因素(尤其是对于死亡率而言),但潜在合并症的影响通常是使用预先定义的慢性病列表来评估的。此外,个体风险因素的计数对于基于人群的“分层与保护”策略的适用性有限。我们旨在开发并验证一种COVID-19风险分层系统,该系统能够基于严重COVID-19的多变量模型,将普通人群个体分为四个相互排斥的风险类别,严重COVID-19是住院、转入重症监护病房(ICU)以及普通人群死亡率的综合指标。该模型是利用2020年3月1日至9月15日期间在加泰罗尼亚(西班牙东北部;750万人)全体人口中经历COVID-19事件(即因COVID-19住院、入住ICU或死亡)的所有个体的临床、医院和流行病学数据开发的,并使用一个独立数据集进行验证,该数据集包含218,329名经逆转录聚合酶链反应(RT-PCR)确诊为COVID-19的个体,这些个体是在模型开发后被感染的。未定义排除标准。最终模型包括年龄、性别、合并症负担的综合指标、社会经济地位以及存在可能与严重COVID-19相关的特定诊断。验证显示该模型具有较高的区分能力,对于住院情况,接受者操作特征曲线下面积为0.85(95%置信区间0.85 - 0.85);对于转入ICU情况,曲线下面积为0.86(0.86 - 0.97);对于死亡情况,曲线下面积为0.96(0.96 - 0.96)。我们的结果为临床医生和政策制定者提供了一种基于证据的工具,用于在除了接触SARS-CoV-2风险较高人群和一线工作人员之外的其他人群中,为COVID-19医疗资源分配确定优先顺序。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d2f/8885698/bb350e3e7912/41598_2022_7138_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d2f/8885698/9f3960535335/41598_2022_7138_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d2f/8885698/8bc9eea37b5e/41598_2022_7138_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d2f/8885698/01ba903639b4/41598_2022_7138_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d2f/8885698/bb350e3e7912/41598_2022_7138_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d2f/8885698/9f3960535335/41598_2022_7138_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d2f/8885698/8bc9eea37b5e/41598_2022_7138_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d2f/8885698/01ba903639b4/41598_2022_7138_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d2f/8885698/bb350e3e7912/41598_2022_7138_Fig4_HTML.jpg

相似文献

1
Development and validation of a population-based risk stratification model for severe COVID-19 in the general population.一般人群中重症 COVID-19 的基于人群的风险分层模型的开发与验证
Sci Rep. 2022 Feb 28;12(1):3277. doi: 10.1038/s41598-022-07138-y.
2
Development and validation of a prognostic model based on comorbidities to predict COVID-19 severity: a population-based study.基于合并症的 COVID-19 严重程度预测预后模型的建立和验证:一项基于人群的研究。
Int J Epidemiol. 2021 Mar 3;50(1):64-74. doi: 10.1093/ije/dyaa209.
3
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
4
Development and Validation of a Multivariable Predictive Model for Mortality of COVID-19 Patients Demanding High Oxygen Flow at Admission to ICU: AIDA Score.发展和验证一个多变量预测模型,用于预测需要高流量氧气通气的 ICU 入院 COVID-19 患者的死亡率:AIDA 评分。
Oxid Med Cell Longev. 2021 Jun 30;2021:6654388. doi: 10.1155/2021/6654388. eCollection 2021.
5
Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study.苏格兰 COVID-19 合并症和治疗的快速流行病学分析(REACT-SCOT):一项基于人群的病例对照研究。
PLoS Med. 2020 Oct 20;17(10):e1003374. doi: 10.1371/journal.pmed.1003374. eCollection 2020 Oct.
6
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
7
Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.在医院环境中评估羟氯喹化学预防 SARS-CoV2 感染在医护人员中的疗效和安全性的对照、双盲、随机试验:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):472. doi: 10.1186/s13063-020-04400-4.
8
Characteristics Associated With Racial/Ethnic Disparities in COVID-19 Outcomes in an Academic Health Care System.在学术医疗体系中,与新冠疫情结果的种族/民族差异相关的特征。
JAMA Netw Open. 2020 Oct 1;3(10):e2025197. doi: 10.1001/jamanetworkopen.2020.25197.
9
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.氯喹或羟氯喹预防和治疗 COVID-19。
Cochrane Database Syst Rev. 2021 Feb 12;2(2):CD013587. doi: 10.1002/14651858.CD013587.pub2.
10
Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort Collaborative.利用美国国家 COVID 队列协作的数据,对美国成年人中 SARS-CoV-2 感染的临床特征和临床严重程度进行临床描述和预测。
JAMA Netw Open. 2021 Jul 1;4(7):e2116901. doi: 10.1001/jamanetworkopen.2021.16901.

引用本文的文献

1
A 25-Year Retrospective of Health IT Infrastructure Building: The Example of the Catalonia Region.25 年健康信息技术基础设施建设回顾:以加泰罗尼亚地区为例。
J Med Internet Res. 2024 Nov 18;26:e58933. doi: 10.2196/58933.
2
Sociodemographic Profile and Risk Factors for the Evolution of Patients with COVID-19 in ICUs in Brazil: A Cross-Sectional Study.巴西 ICU 中 COVID-19 患者的社会人口学特征和演变的危险因素:一项横断面研究。
ScientificWorldJournal. 2024 Jul 15;2024:2927407. doi: 10.1155/2024/2927407. eCollection 2024.
3
Economic impact of inflammatory bowel disease in Catalonia: a population-based analysis.

本文引用的文献

1
Age is the main determinant of COVID-19 related in-hospital mortality with minimal impact of pre-existing comorbidities, a retrospective cohort study.年龄是 COVID-19 相关住院死亡率的主要决定因素,而既往合并症的影响最小,这是一项回顾性队列研究。
BMC Geriatr. 2022 Mar 5;22(1):184. doi: 10.1186/s12877-021-02673-1.
2
Performance of Three Measures of Comorbidity in Predicting Critical COVID-19: A Retrospective Analysis of 4607 Hospitalized Patients.三种合并症测量方法在预测重症新型冠状病毒肺炎中的表现:对4607例住院患者的回顾性分析
Risk Manag Healthc Policy. 2021 Nov 23;14:4729-4737. doi: 10.2147/RMHP.S326132. eCollection 2021.
3
加泰罗尼亚炎症性肠病的经济影响:一项基于人群的分析。
Therap Adv Gastroenterol. 2024 Feb 14;17:17562848231222344. doi: 10.1177/17562848231222344. eCollection 2024.
4
Healthcare risk stratification model for emergency departments based on drugs, income and comorbidities: the DICER-score.基于药物、收入和合并症的急诊科医疗风险分层模型:DICER 评分。
BMC Emerg Med. 2024 Feb 14;24(1):23. doi: 10.1186/s12873-024-00946-7.
5
Disparities and effectiveness of COVID-19 vaccine policies in three representative European countries.三个代表性欧洲国家的 COVID-19 疫苗政策的差异和效果。
Int J Equity Health. 2024 Jan 30;23(1):16. doi: 10.1186/s12939-024-02110-w.
6
Is Age the Most Important Risk Factor in COVID-19 Patients? The Relevance of Comorbidity Burden: A Retrospective Analysis of 10,551 Hospitalizations.年龄是新冠病毒肺炎患者最重要的风险因素吗?合并症负担的相关性:对10551例住院病例的回顾性分析
Clin Epidemiol. 2023 Jun 30;15:811-825. doi: 10.2147/CLEP.S408510. eCollection 2023.
7
Prioritization of COVID-19 risk factors in July 2020 and February 2021 in the UK.2020年7月和2021年2月英国新冠病毒病风险因素的优先级划分
Commun Med (Lond). 2023 Mar 30;3(1):45. doi: 10.1038/s43856-023-00271-3.
8
Risk Stratification Model for Severe COVID-19 Disease: A Retrospective Cohort Study.重症新型冠状病毒肺炎疾病风险分层模型:一项回顾性队列研究。
Biomedicines. 2023 Mar 2;11(3):767. doi: 10.3390/biomedicines11030767.
9
Prognostic models in COVID-19 infection that predict severity: a systematic review.COVID-19 感染中预测严重程度的预后模型:系统评价。
Eur J Epidemiol. 2023 Apr;38(4):355-372. doi: 10.1007/s10654-023-00973-x. Epub 2023 Feb 25.
10
Start-up of a high-risk COVID unit: The experience from a general hospital.启动一个高风险新冠病房:一家综合医院的经验
Med Clin (Engl Ed). 2023 Feb 24;160(4):172-178. doi: 10.1016/j.medcle.2022.10.009. Epub 2023 Feb 2.
Performance of quantitative measures of multimorbidity: a population-based retrospective analysis.
多病症定量指标的表现:基于人群的回顾性分析。
BMC Public Health. 2021 Oct 18;21(1):1881. doi: 10.1186/s12889-021-11922-2.
4
Risk factors for COVID-19 diagnosis, hospitalization, and subsequent all-cause mortality in Sweden: a nationwide study.瑞典 COVID-19 诊断、住院和随后全因死亡率的危险因素:一项全国性研究。
Eur J Epidemiol. 2021 Mar;36(3):287-298. doi: 10.1007/s10654-021-00732-w. Epub 2021 Mar 11.
5
COVID-19 mortality in the UK Biobank cohort: revisiting and evaluating risk factors.英国生物库队列中 COVID-19 的死亡率:重新审视和评估风险因素。
Eur J Epidemiol. 2021 Mar;36(3):299-309. doi: 10.1007/s10654-021-00722-y. Epub 2021 Feb 15.
6
SARS-CoV-2 structural features may explain limited neutralizing-antibody responses.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的结构特征可能解释了中和抗体反应有限的原因。
NPJ Vaccines. 2021 Jan 4;6(1):2. doi: 10.1038/s41541-020-00264-6.
7
Development and validation of the patient history COVID-19 (PH-Covid19) scoring system: a multivariable prediction model of death in Mexican patients with COVID-19.患者病史 COVID-19(PH-Covid19)评分系统的开发和验证:墨西哥 COVID-19 患者死亡的多变量预测模型。
Epidemiol Infect. 2020 Nov 26;148:e286. doi: 10.1017/S0950268820002903.
8
Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: an observational cohort study.系统评价和外部验证 22 种住院成人 COVID-19 预后模型:一项观察性队列研究。
Eur Respir J. 2020 Dec 24;56(6). doi: 10.1183/13993003.03498-2020. Print 2020 Dec.
9
Fairly Prioritizing Groups for Access to COVID-19 Vaccines.合理确定获得新冠疫苗的优先群体
JAMA. 2020 Oct 27;324(16):1601-1602. doi: 10.1001/jama.2020.18513.
10
An inflammatory cytokine signature predicts COVID-19 severity and survival.炎症细胞因子特征可预测 COVID-19 严重程度和存活情况。
Nat Med. 2020 Oct;26(10):1636-1643. doi: 10.1038/s41591-020-1051-9. Epub 2020 Aug 24.